18 reports

Metabolex CymaBay Therapeutics Sanofi World Type ## Diabetes Drug Development Therapy Hospital Insulin Research And Development Gliptins Diabetes

  • Type 2 Diabetes
  • Pharmaceutical
  • World
  • Japan
  • Smoking Prevalence
  • LED Export

Japan United States European Union Therapy Type ## Diabetes Gliptins

  • Clinical Trial
  • Type 2 Diabetes
  • Japan
  • India
  • China
  • United States
  • Drug Approval
  • Prescription Drug Sales

This study covers the latent demand outlook for diabetes drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or...

  • Diabetes
  • India
  • United States
  • Disposable Income
  • Purchasing Power Parity

This study covers the latent demand outlook for diabetes drugs across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to...

  • Diabetes
  • China
  • Disposable Income
  • Purchasing Power Parity

South Korea Hepatitis Treatment Gliptins Vitamin Influenza HIV Antiviral

  • Healthcare
  • South Korea
  • World
  • Direct Sales
  • Health Expenditure

Zemiglo is an antidiabetic drug and a DPP## inhibitor developed by LG Life Sciences for the treatment of type II diabetes.

  • Pharmaceutical
  • Healthcare
  • South Korea

Under the agreement, Salubris received China rights for DPP## inhibitor known as fotagliptin benzoate, for CNY##m (US$##.##m).

  • Pharmaceutical
  • Healthcare
  • Private Placement
  • World
  • Austria
  • Israel
  • Medical Technology Density
  • Foreign Direct Investment

Under the agreement, Salubris received China rights for DPP## inhibitor known as fotagliptin benzoate, for CNY##m (US$##.##m).

  • Pharmaceutical
  • Biotechnology
  • Sichuan
  • Medical Technology Density

Under the agreement, Salubris received China rights for DPP## inhibitor known as fotagliptin benzoate, for CNY##m (US$##.##m).

  • Pharmaceutical
  • Private Placement
  • China
  • Austria
  • Pharmaceutical Production
  • Medical Technology Density

Taiwan South Korea United States Sodium-Glucose Co-Transporter ## Inhibitor Therapy Gliptins

  • Therapy
  • World
  • Southeast Asia
  • Drug Approval
  • Inflation Rate

China India Prescriptions Filled Pharmaceutical Therapy Cardiology Gliptins Calcium Channel Blocker

  • Pharmaceutical
  • China
  • India
  • Brazil
  • Russia
  • Health Expenditure
  • Spending On Medicines

Zemiglo is an antidiabetic drug and a DPP## inhibitor developed by LG Life Sciences for the treatment of type II diabetes.

  • South Korea
  • Depression Prevalence

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP## inhibitor, SGLT## inhibitor, biguanide, sulphonylurea and GLP## receptor agonist.

  • Pharmaceutical
  • Healthcare
  • Japan
  • France
  • United States
  • Pharmaceutical Exports

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Company, Limited have agreed to form a strategic sales alliance to conduct joint sales activities for DPP## inhibitor, MP-##, and SGLT## inhibitor, TA-##, which are under development by Tanabe in Japan for the treatment of type II diabetes mellitus.

  • Private Placement
  • Japan
  • Canada
  • Prescription Drug Sales
  • LED Export

It is a gliptin class of anti-diabetic agents.

  • Vaccine
  • Infectious Disease
  • Therapy
  • World
  • Yamagata Prefecture
  • Pharmaceutical Registrations
  • Drug Approval

In 2003, PPD entered into a collaboration agreement to develop Syrrx s orally active DPP## inhibitors to treat type ## diabetes and other major human diseases.

  • Therapy
  • Monoclonal Antibody
  • Vaccine
  • Infectious Disease
  • Cardiovascular Drug
  • Oncology
  • United States
  • Japan
  • Diagnostic Imaging Density
  • Drug Approval

In July 2005, Takeda Pharmaceutical Company Limited and PPD, Inc. announced an agreement in which Takeda acquired the development and marketing rights to all dipeptidyl peptidase IV (DPP##) inhibitors previously granted to PPD under an agreement between PPD and Syrrx, Inc. Under the new agreement, Takeda, through Takeda San Diego, acquired all the remaining rights to develop and commercialize the DPP## inhibitors, which rights had been shared by PPD and Takeda San Diego under the collaboration agreement dated November ##.

  • Research And Development
  • World
  • United States
  • China
  • Drug Approval
  • Patients Undergoing Dialysis

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Company, Limited have agreed to form a strategic sales alliance to conduct joint sales activities for DPP## inhibitor, MP-##, and SGLT## inhibitor, TA-##, which are under development by Tanabe in Japan for the treatment of type II diabetes mellitus.

  • Pharmaceutical
  • Financial Services
  • Japan
  • United States
  • India
  • Prescription Drug Sales
  • Cosmetics Revenue